Rapidly spreading outbreak of the novel Severe Acute Respiratory Syndrome Coronavirus-2
(SARS-CoV-2) is causing serious health concerns worldwide. It started as an epidemic in …

In December 2019, a new coronavirus, named severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2), emerged from China, causing pneumonia outbreaks first in …

We propose a new hypothesis that the established drug pentoxifylline deserves attention as
a potential repurposed therapeutic for COVID‐19. Pentoxifylline is an immunomodulator with …

The world is facing a viral pandemic of a new coronavirus called COVID‐19. Pentoxifylline is
a methyl‐xanthine derivative and it inhibits the phosphodiesterase IV (PDE IV). This drug is …

Pentoxifylline (PTX) has broad-spectrum properties such as anti-inflammatory,
anticoagulant, and antiviral effects. The aim of this study was to evaluate the efficacy and …

The existing pandemic viral infection caused by severe acute respiratory syndrome
coronavirus type 2 (SARS-CoV-2) leads to coronavirus disease 2019 (Covid-19). SARS …

At more than 10 months after the first case of COVID-19 was documented, the understanding
of the pathogenesis of this viral illness is growing on a daily basis. A massive pro …

Although most patients with coronavirus disease 2019 (COVID-19) have a good prognosis,
in some cases, the disease progresses rapidly, and the mortality rate is high. Some …

Accumulating evidence suggests that a subgroup of patients with COVID-19 might suffer
from severe complications, such as acute respiratory distress syndrome (ARDS) …

COVID-19 pandemic presents an unprecedented challenge to identify effective drugs for
treatment. Despite multiple clinical trials using different agents, there is still a lack of specific …